Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Herborium Group, Inc. (HBRM)
Fort Lee, NJ, US
Herborium Group, Inc. operates as a specialized firm in botanical therapeutics, focusing on the creation, licensing, and commercialization of its unique, plant-based medicinal goods for both general consumers and healthcare professionals. Its product range includes dermatological solutions like AcnEase, an herbal treatment designed to alleviate symptoms associated with hormonal acne and various forms of Rosacea. The company also offers the AcnEase Skin Management System, intended to diminish acne marks and scars. Furthermore, Herborium provides non-prescription sexual health and performance products. These serve as alternatives for specific sexual dysfunctions that may arise from cardiovascular conditions, the use of antidepressants, or surgical procedures such as hysterectomies. The company also offers energy-boosting products, notably Lasting Energy. This herbal supplement aims to reduce hangover effects, counteract jet lag, and address general energy depletion caused by intense physical activities, high stress levels, prolonged sexual engagements, or other enduring or temporary physical demands. Additional products in its portfolio include the Liver Activator Series for managing liver damage; ProstAid, a natural remedy specifically formulated for Benign Prostate Hyperplasia (BPH); and CardioVitae, a fermentation-based product utilizing a Lucidium-derived cell line to target cardio-pulmonary insufficiencies. Herborium Group, Inc. distributes its products across the United States, the United Kingdom, and mainland Europe, utilizing a network of distributors, specialty retailers, and its e-commerce platform. The company was founded in 2000 and has its principal office located in Fort Lee, New Jersey.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -90.00% | -90.00% | +900.00% | -80.00% | +900.00% | -90.00% | -99.44% | -90.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-25.0% Q1'26: +17.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%—
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-32.9% Q1'26: -2.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-30.2% Q1'26: -11.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +3.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-4.49× Q1'26: -8.51× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Agnes Olszewski | Founder, Chairman, Chief Executive Officer, President, Chief Financial Officer & Principal Accounting Officer | 150.0K | — |
| James Gilligan MSIB | Co-Founder, Scientific Advisor & Director | 66.7K | — |
| Daniel Teo | Senior Vice President of Business Development | — | male |
| John E. Donahue | Controller & SEC Advisor | — | male |
| Lawrence Woo | Asia Business Advisor & Director | — | male |
| Roger Jones | UK & EU Advisor and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HBRM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
